{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:24:55Z","timestamp":1791591895848,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"DOI":"10.7759\/cureus.26233","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:09:07Z","timestamp":1655986147000},"source":"Crossref","is-referenced-by-count":6,"title":["Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review"],"prefix":"10.7759","author":[{"given":"Ekaterina","family":"Proskuriakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat M","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andr\u00e9 F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015, 21:2684-94. 10.1158\/1078-0432.CCR-14-2329","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain A","year":"2018","unstructured":"Jain A, Borad MJ, Kelley RK, et al.. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. 2018, 2:1-12. 10.1200\/PO.17.00080","journal-title":"JCO Precis Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery MA","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, et al.. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018, 24:4154-61. 10.1158\/1078-0432.CCR-18-0078","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater JA","year":"2016","unstructured":"Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016, 35:e194-203. 10.1200\/EDBK_160831","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel T","year":"2001","unstructured":"Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001, 33:1353-7. 10.1053\/jhep.2001.25087","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040201","article-title":"Liver fluke induces cholangiocarcinoma","volume":"4","author":"Sripa B","year":"2007","unstructured":"Sripa B, Kaewkes S, Sithithaworn P, et al.. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007, 4:e201. 10.1371\/journal.pmed.0040201","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1132","article-title":"Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer","volume":"89","author":"Zatonski WA","year":"1997","unstructured":"Zatonski WA, Lowenfels AB, Boyle P, et al.. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997, 89:1132-8. 10.1093\/jnci\/89.15.1132","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"24","author":"Massarweh NN","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017, 24:1073274817729245. 10.1177\/1073274817729245","journal-title":"Cancer Control"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.62","article-title":"Roles of liver fluke infection as risk factor for cholangiocarcinoma","volume":"21","author":"Sithithaworn P","year":"2014","unstructured":"Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014, 21:301-8. 10.1002\/jhbp.62","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22756","article-title":"Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China","volume":"121","author":"Hsing AW","year":"2007","unstructured":"Hsing AW, Bai Y, Andreotti G, et al.. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer. 2007, 121:832-8. 10.1002\/ijc.22756","journal-title":"Int J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle JW","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021, 397:428-44. 10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.24810","article-title":"MRI of cholangiocarcinoma","volume":"42","author":"Jhaveri KS","year":"2015","unstructured":"Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015, 42:1165-79. 10.1002\/jmri.24810","journal-title":"J Magn Reson Imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis","volume":"71","author":"Lamarca A","year":"2019","unstructured":"Lamarca A, Barriuso J, Chander A, et al.. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J Hepatol. 2019, 71:115-29. 10.1016\/j.jhep.2019.01.038","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2018.09.004","article-title":"Dilemma of elevated CA 19-9 in biliary pathology","volume":"18","author":"Tsen A","year":"2018","unstructured":"Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018, 18:862-7. 10.1016\/j.pan.2018.09.004","journal-title":"Pancreatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2331031446","article-title":"Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP","volume":"233","author":"Park MS","year":"2004","unstructured":"Park MS, Kim TK, Kim KW, et al.. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology. 2004, 233:234-40. 10.1148\/radiol.2331031446","journal-title":"Radiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655775","article-title":"Emerging technologies for the diagnosis of perihilar cholangiocarcinoma","volume":"38","author":"Rizvi S","year":"2018","unstructured":"Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging technologies for the diagnosis of perihilar cholangiocarcinoma. Semin Liver Dis. 2018, 38:160-9. 10.1055\/s-0038-1655775","journal-title":"Semin Liver Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu YM","year":"2013","unstructured":"Wu YM, Su F, Kalyana-Sundaram S, et al.. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013, 3:636-47. 10.1158\/2159-8290.CD-13-0050","journal-title":"Cancer Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi CR","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, et al.. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014, 9:e115383. 10.1371\/journal.pone.0115383","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno M","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T, et al.. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020, 20:1105. 10.1186\/s12885-020-07365-4","journal-title":"BMC Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose JN","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al.. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019, 20:663-73. 10.1016\/S1470-2045(18)30915-X","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal A","year":"2020","unstructured":"Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020, 155:103091. 10.1016\/j.critrevonc.2020.103091","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \"prime time\" in biliary tract\u00a0cancer","volume":"73","author":"Lamarca A","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for \"prime time\" in biliary tract\u00a0cancer. J Hepatol. 2020, 73:170-85. 10.1016\/j.jhep.2020.03.007","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle MM","year":"2021","unstructured":"Javle MM, Roychowdhury S, Kelley RK, et al.. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. Journal of Clinical Oncology. 2021, 39:265. 10.1200\/JCO.2021.39.3_suppl.265","journal-title":"Journal of Clinical Oncology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle J","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al.. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362:1273-81. 10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka T","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al.. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010, 103:469-74. 10.1038\/sj.bjc.6605779","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.430","article-title":"Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations","volume":"40","author":"Feng Y-H","year":"2022","unstructured":"Feng Y-H, Su W-C, Oh D-Y, et al.. Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations. Journal of Clinical Oncology. 2022, 40:430. 10.1200\/JCO.2022.40.4_suppl.430","journal-title":"Journal of Clinical Oncology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera TP","year":"2017","unstructured":"Perera TP, Jovcheva E, Mevellec L, et al.. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017, 16:1010-20. 10.1158\/1535-7163.MCT-16-0589","journal-title":"Mol Cancer Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15139","article-title":"Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers","volume":"112","author":"Zhang R","year":"2021","unstructured":"Zhang R, Puzzoni M, Mariani S, et al.. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci. 2021, 112:4819-33. 10.1111\/cas.15139","journal-title":"Cancer Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1896247","article-title":"Novel approaches for the management of biliary tract cancer: today and tomorrow","volume":"30","author":"Rizzo A","year":"2021","unstructured":"Rizzo A. Novel approaches for the management of biliary tract cancer: today and tomorrow. Expert Opin Investig Drugs. 2021, 30:295-7. 10.1080\/13543784.2021.1896247","journal-title":"Expert Opin Investig Drugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation","volume":"11","author":"Hall TG","year":"2016","unstructured":"Hall TG, Yu Y, Eathiraj S, et al.. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 2016, 11:e0162594. 10.1371\/journal.pone.0162594","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro V","year":"2019","unstructured":"Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al.. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019, 120:165-71. 10.1038\/s41416-018-0334-0","journal-title":"Br J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1901192","article-title":"A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps","volume":"30","author":"Rizzo A","year":"2021","unstructured":"Rizzo A, Brandi G. A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps. Expert Opin Investig Drugs. 2021, 30:279. 10.1080\/13543784.2021.1901192","journal-title":"Expert Opin Investig Drugs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al.. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21:671-84. 10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti G","year":"2020","unstructured":"Lamberti G, Andrini E, Sisi M, et al.. Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol. 2020, 156:103119. 10.1016\/j.critrevonc.2020.103119","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar RJ","year":"2018","unstructured":"Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJ. Wild-type and mutated IDH1\/2 enzymes and therapy responses. Oncogene. 2018, 37:1949-60. 10.1038\/s41388-017-0077-z","journal-title":"Oncogene"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108774","article-title":"IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma","volume":"113","author":"Zhang X","year":"2019","unstructured":"Zhang X, Miao R, Liu T, et al.. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma. Biomed Pharmacother. 2019, 113:108774. 10.1016\/j.biopha.2019.108774","journal-title":"Biomed Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.11.024","article-title":"Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas","volume":"90","author":"Delahousse J","year":"2018","unstructured":"Delahousse J, Verlingue L, Broutin S, et al.. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Eur J Cancer. 2018, 90:83-91. 10.1016\/j.ejca.2017.11.024","journal-title":"Eur J Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal L","year":"2015","unstructured":"Goyal L, Govindan A, Sheth RA, et al.. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015, 20:1019-27. 10.1634\/theoncologist.2015-0210","journal-title":"Oncologist"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al.. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020, 21:796-807. 10.1016\/S1470-2045(20)30157-1","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu AX","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al.. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021, 7:1669-77. 10.1001\/jamaoncol.2021.3836","journal-title":"JAMA Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris ER","year":"2011","unstructured":"Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011, 10:385-94. 10.1158\/1535-7163.MCT-10-0799","journal-title":"Mol Cancer Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo M","year":"2014","unstructured":"Simbolo M, Fassan M, Ruzzenente A, et al.. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014, 5:2839-52. 10.18632\/oncotarget.1943","journal-title":"Oncotarget"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu A","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016, 1:e000023. 10.1136\/esmoopen-2015-000023","journal-title":"ESMO Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial","volume":"37","author":"Wainberg ZA","year":"2019","unstructured":"Wainberg ZA, Lassen UN, Elez E, et al.. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. Journal of Clinical Oncology. 2019, 37:187. 10.1200\/JCO.2019.37.4_suppl.187","journal-title":"Journal of Clinical Oncology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross JS","year":"2014","unstructured":"Ross JS, Wang K, Gay L, et al.. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014, 19:235-42. 10.1634\/theoncologist.2013-0352","journal-title":"Oncologist"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al.. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:271-82. 10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, et al.. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020, 21:531-40. 10.1016\/S1470-2045(19)30856-3","journal-title":"Lancet Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser MM","year":"2007","unstructured":"Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007, 26:6469-87. 10.1038\/sj.onc.1210477","journal-title":"Oncogene"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy S","year":"2017","unstructured":"Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, Valle JW. HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer Metastasis Rev. 2017, 36:141-57. 10.1007\/s10555-016-9645-x","journal-title":"Cancer Metastasis Rev"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle JW","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017, 7:943-62. 10.1158\/2159-8290.CD-17-0245","journal-title":"Cancer Discov"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle M","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, et al.. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021, 22:1290-300. 10.1016\/S1470-2045(21)00336-3","journal-title":"Lancet Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.320","article-title":"Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT \u2018basket\u2019 trial","volume":"39","author":"Harding JJ","year":"2021","unstructured":"Harding JJ, Cleary JM, Quinn DI, et al.. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT \u2018basket\u2019 trial. Journal of Clinical Oncology. 2021, 39:320. 10.1200\/JCO.2021.39.3_suppl.320","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96737-current-targeted-therapy-options-in-the-treatment-of-cholangiocarcinoma-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:44Z","timestamp":1707507464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96737-current-targeted-therapy-options-in-the-treatment-of-cholangiocarcinoma-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.26233","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}